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S U M M A R Y
Objectives: Diabetes is a risk factor for active tuberculosis (TB). Data are limited regarding the association
between diabetes and TB drug resistance and treatment outcomes. We examined characteristics of TB
patients with and without diabetes in a Peruvian cohort at high risk for drug-resistant TB. Among TB
patients with diabetes (TB–DM), we studied the association between diabetes clinical/management
characteristics and TB drug resistance and treatment outcomes.
Methods: During 2005–2008, adults with suspected TB with respiratory symptoms in Lima, Peru, who
received rapid drug susceptibility testing (DST), were prospectively enrolled and followed during
treatment. Bivariate and Kaplan–Meier analyses were used to examine the relationships of diabetes
characteristics with drug-resistant TB and TB outcomes.
Results: Of 1671 adult TB patients enrolled, 186 (11.1%) had diabetes. TB–DM patients were signiﬁcantly
more likely than TB patients without diabetes to be older, have had no previous TB treatment, and to
have a body mass index (BMI) >18.5 kg/m2 (p < 0.05). In patients without and with previous TB
treatment, the prevalence of multidrug-resistant TB was 23% and 26%, respectively, among patients
without diabetes, and 12% and 28%, respectively, among TB–DM patients. Among 149 TB–DM patients
with DST results, 104 (69.8%) had drug-susceptible TB and 45 (30.2%) had drug-resistant TB, of whom 29
had multidrug-resistant TB. There was no association between diabetes characteristics and drug-
resistant TB. Of 136 TB–DM patients with outcome information, 107 (78.7%) had a favorable TB outcome;
active diabetes management was associated with a favorable outcome.
Conclusions: Diabetes was common in a cohort of TB patients at high risk for drug-resistant TB. Despite
prevalent multidrug-resistant TB among TB–DM patients, the majority had a favorable TB treatment
outcome.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Globally, there are an estimated 8.8 million new tuberculosis
(TB) cases each year, and approximately 340 million people
are living with diabetes.1,2 Diabetes is a known risk factor for the
development of active TB,3–5 and an estimated 15% of patients
with TB in countries with a high TB burden have diabetes.6
The association between diabetes and TB is an area of growing
interest due to the persistently high prevalence of both* Corresponding author. Tel.: +1 404 639 2658; fax: +1 404 639 1566.
E-mail address: dpu2@cdc.gov (E. Bloss).
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http://dx.doi.org/10.1016/j.ijid.2012.12.029diseases internationally and the expected increase in diabetes
incidence and deaths over the coming decades.2,7,8
Due to global increases in multidrug-resistant TB (MDR-TB),9 the
importance of understanding the relationship between diabetes and
MDR-TB is growing.10 For example, studies from India, the
Philippines, Spain, and Turkey have shown that diabetes is prevalent
among patients with MDR-TB, with 10–23% of MDR-TB patients
having concomitant diabetes.11–14 Other studies have reported an
independent association between diabetes and MDR-TB,15,16 but
data are limited regarding factors associated with drug resistance
among TB patients with diabetes (TB–DM). Furthermore, among TB–
DM patients, there remains a paucity of information about the
relationship between diabetes control and clinical care character-
istics and TB outcomes.4,17ses. Published by Elsevier Ltd. All rights reserved.
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middle-income countries, where the largest increases in
diabetes prevalence and incidence are expected during the next
20 years.4,8 In 2009, the incidence of TB in Peru was 113 per
100 000 persons, which is the highest in South America.18 The
national prevalence of MDR-TB among patients never treated
and previously treated for TB (one of the strongest known risk
factors for MDR-TB) is also high, at 5.0% and 23.6%, respectively.9
Similarly, there is a growing burden of diabetes in Peru. The
prevalence of diabetes in urban areas was recently reported to
be 7.0%;14 based on limited data, the national prevalence is
estimated to be 5.1–6.0% among adults19 and is expected to
increase to 7.3% by 2030.7 Given the high burden of TB and
diabetes in Peru, the complexities in managing patients with
these co-morbidities, and the challenges that exist in linking TB
and diabetes services, it is important to better understand the
relationship between diabetes and drug-resistant TB to help
inform efforts to optimize patient care. Therefore, in this study
we aimed to (1) describe the characteristics of TB patients
screened for MDR-TB in Peru with and without diabetes; (2)
describe the diabetes clinical characteristics and medical care
associated with drug resistance among patients with TB and
diabetes; and (3) determine diabetes care characteristics
associated with favorable TB treatment outcomes.
2. Methods
2.1. Setting and program description
In 2005, the Peruvian National Tuberculosis Program (PNTP)
and the National Reference Laboratory (NRL) initiated a pilot
program in two districts in Lima to strengthen its TB laboratory
network, implement rapid diagnostic strategies for drug-resistant
TB, and decentralize drug susceptibility testing (DST) to district
laboratories.20 Patients with risk factors for MDR-TB, as deﬁned by
the PNTP, had rapid screening for drug-resistant TB using DST by
the direct nitrate reductase assay (Griess method). Diabetes was
one of the indications for rapid DST per the PNTP criteria.21
Additional details about this programmatic strategy of rapid
screening for MDR-TB have been described elsewhere.20,22,23
2.2. Data collection
Patients who had suspected or conﬁrmed TB were prospectively
enrolled in two (of four) health districts of Lima from January 2005
through May 2008. Health care workers from 54 health centers in
Lima Ciudad and Lima Este identiﬁed patients with risk factors for
MDR-TB, and then patient sputum samples were sent to the district
laboratory for DST. Observational data were collected on all
individuals referred for DST using standardized data collection
forms. For TB patients, HIV status was recorded as a part of the
routine PNTP guidelines. Chest radiographs performed <1 year
before the enrollment date or <1 month after the enrollment date
were reviewed. Socio-demographic, clinical, bacteriologic, and risk
factor data were also collected at baseline. Patients were then
followed throughout TB treatment.
Patients with diabetes were identiﬁed from their history
recorded in the medical records. From each of these patients,
information about date of diabetes diagnosis, result, and type of
last glucose test were collected. To supplement these data,
additional diabetes-related information from before and during
TB treatment were abstracted from existing records at health
clinics and hospitals in Lima where patients with diabetes received
medical care. The following information was collected: type and
date of diabetes diagnosis, type of medications used, diabetes-
related care and complications prior to and during enrollment, andlaboratory results during the year prior to and during study
enrollment.
2.3. Deﬁnitions
Deﬁnitions of MDR-TB and diabetes as deﬁned by the World
Health Organization (WHO) were used for this project.24,25
MDR-TB was deﬁned as infection with Mycobacterium tubercu-
losis with in vitro resistance to at least isoniazid and rifampin.
Drug-resistant TB was deﬁned as M. tuberculosis with in vitro
resistance to any ﬁrst-line anti-TB drug. Patients identiﬁed as
having diabetes in the medical records had their diabetes
conﬁrmed by any one of the following criteria: fasting plasma
glucose 7.0 mmol/l (126 mg/dl), 2-h plasma glucose/random
blood glucose 11.1 mmol/l (200 mg/dl), glycosylated hemo-
globin (HbA1c) 7.0%, or treatment with insulin or oral
hypoglycemic agents. Any values for HbA1c or urine glucose
during the previous year before enrollment start date were also
recorded. Diabetes control was deﬁned by documentation of
controlled diabetes status by a nurse or physician in the
patient’s medical records prior to TB treatment. Diabetes care
during TB treatment was deﬁned using a combination of the
following measures: recorded endocrinologist visit, diabetes
control documented in the medical record, recorded use of
diabetes medications, or three or more measures of blood
glucose. The level of diabetes care during treatment was deﬁned
as frequent care (three or four of the measures mentioned
above), some care (one or two measures), and none (0
measures). A favorable TB treatment outcome was deﬁned as
cured or completed, and a poor treatment outcome was deﬁned
as default, failed, or died, in accordance with WHO guidelines.26
If ﬁnal outcome information was unavailable, converted sputum
culture during treatment was also considered favorable.
2.4. Data management and analyses
Data were double-entered into an Epi-Info database (Centers
for Disease Control and Prevention (CDC), Atlanta, GA, USA). All
analyses were performed using SAS 9.3 (Cary, NC, USA). We limited
our analysis to all adult (15 years) TB patients who were enrolled
into the study during January 2005–May 2008. Patients aged less
than 15 years were excluded from the analysis because both
childhood diabetes (primarily type 1) and TB differ clinically from
adult disease. TB–DM patients were excluded from analyses of the
association of diabetes characteristics (prior to TB treatment) with
drug resistance pattern if TB drug susceptibility data were not
available (n = 35).
The Chi-square test or Fisher’s exact test was used to
calculate p-values for categorical variables. The Student’s t-test
and analysis of variance (ANOVA) were used to compare
differences in normally distributed continuous variables, and
the Wilcoxon–Mann–Whitney rank sums test was used when
continuous variables were not normally distributed. The
associations between patient characteristics and study out-
comes were examined in bivariate analyses. A two-sided p-value
of less than 0.05 was considered statistically signiﬁcant
throughout the analyses. Product limit survival estimates were
created using Kaplan–Meier curves, and the log-rank test was
used to evaluate statistical difference in survival time. Cox
proportional hazards models were used to estimate the rate of
culture conversion using survival time. Time to TB culture
conversion for survival estimation was calculated as the number
of days between the date a sputum sample was sent for DST and
the ﬁrst date a negative sputum sample was collected that was
followed by at least one additional consecutive negative sputum
sample 30 days apart.
Table 1
Characteristics of adult tuberculosis patients with and without diabetes screened for drug-resistant tuberculosis in Lima, Peru, 2005–2008 (N = 1671)
Characteristics TB with DM, n (%)
(n = 186)






Male 114 (61.3) 989 (66.6) 1103 (66.0)
Female 72 (38.7) 496 (38.7) 568 (34.0)
Age, yearsa
15–24 0 506 (34.1) 506 (30.3)
25–44 33 (17.7) 714 (30.1) 747 (44.7)
45–64 125 (67.2) 218 (14.7) 343 (20.5)
>64 28 (15.1) 47 (3.2) 75 (4.5)
Marital statusa
Married/partner 122 (65.6) 521 (35.1) 643 (38.5)
Divorced/separated/widow 37 (19.9) 172 (11.6) 209 (12.5)
Single 27 (14.5) 791 (53.3) 818 (49.0)
Employment
Employed/otherb 123 (66.1) 885 (59.6) 1008 (60.3)
Unemployed 63 (33.9) 596 (40.1) 659 (39.4)
Educationa
None/incomplete primary 48 (25.8) 170 (11.5) 218 (13.1)
Some secondary 52 (28.0) 482 (32.5) 534 (32.0)
Graduated secondary or more 85 (45.7) 824 (55.5) 909 (54.4)
TB characteristics
Baseline AFB smear result
Positive 171 (91.9) 1303 (87.7) 1474 (88.2)
Negative 14 (7.5) 161 (10.8) 175 (10.5)
Missing 1 (0.5) 21 (1.4) 22 (1.3)
Baseline culture resulta
Positive 138 (74.2) 1059 (71.3) 1197 (71.6)
Negative 24 (12.9) 308 (20.7) 332 (19.9)
Missing 24 (12.9) 118 (8.0) 142 (8.5)
Previous TB treatmenta
Yes 43 (23.1) 805 (54.2) 848 (50.7)
No 143 (76.9) 680 (45.8) 823 (49.3)
Baseline drug susceptibilitya
Pan-susceptible 105 (56.5) 537 (36.2) 642 (38.4)
Drug-resistant 17 (9.1) 137 (9.2) 154 (9.2)
MDR 29 (15.6) 365 (24.6) 394 (23.6)
Missing 35 (18.8) 446 (30.0) 481 (28.8)
Extrapulmonary
Yes 3 (1.6) 34 (2.3) 37 (2.2)
No 183 (98.4) 1450 (97.6) 1633 (97.7)
Duration of symptoms, weeks
Mean (SD) 12.1 (11.6) 15.3 (21.9) 15.0 (21.0)
Median (IQR) 8.7 (11.6) 8.9 (15.9) 8.9 (14.9)
TB symptomsc
Weight loss 158 (85.0) 1205 (81.1) 1363 (81.6)
Dyspnea 25 (13.4) 273 (18.4) 298 (17.8)
Blood in sputum 6 (3.2) 93 (6.3) 99 (5.9)
Bilateral cavitationa
Yes 6 (3.2) 75 (5.1) 81 (4.9)
No 177 (95.2) 1357 (91.4) 1534 (91.8)
Missing 3 (1.6) 53 (3.6) 56 (3.4)
Risk factorsc
HIV-positivea 1 (0.5) 197 (13.3) 198 (11.9)
Any household TB contacta 10 (5.4) 347 (23.4) 357 (21.4)
Household MDR contacta 7 (3.8) 199 (13.4) 206 (12.3)
Current tobacco 9 (4.8) 57 (3.8) 66 (4.0)
Current alcohol 10 (5.4) 125 (8.4) 135 (8.1)
Low BMI (<18.5 kg/m2)a 9 (4.8) 326 (22.2) 335 (20.3)
AFB, acid-fast bacillus; BMI, body mass index; DM, diabetes mellitus; IQR, interquartile range; MDR, multidrug-resistant; SD, standard deviation; TB, tuberculosis. Some cells
may not sum to 100% due to missing data. For any variable with more than 1% missing, percent missing is indicated.
a Mantel–Haenszel p-value <0.05.
b ‘Other’ includes student, housewife, and retired.
c Not mutually exclusive categories, should not add up to 100%, column percentages are listed.
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The institutional review boards at Brigham and Women’s
Hospital and the Peruvian National Institute of Health reviewed
and approved the study. This activity was approved by the
US CDC as program evaluation and not as human subject
research.3. Results
3.1. Characteristics of TB patients screened for MDR-TB in Peru
A total of 1671 adult patients with culture-positive TB were
screened for MDR-TB and enrolled in the prospective cohort
(Figure 1). The majority of patients were male (66%) and the
Figure 1. Tuberculosis (TB) patients at risk for multidrug-resistant TB enrolled,
screened for diabetes mellitus (DM), and followed up for TB treatment outcomes in
Peru.
Figure 2. Anti-tuberculosis (TB) drug susceptibility results for 1671 Peruvian TB
patients with and without diabetes (DM) stratiﬁed by previous TB treatment history
(drug-resistant refers to any resistance to ﬁrst-line drugs, but is not multidrug-
resistant).
Table 2
Diabetes characteristics prior to tuberculosis treatment and tuberculosis risk
factors by drug resistance pattern among tuberculosis patients with diabetes in









DM-related factors prior to TB treatment
Type of DM
Type 2 86 (82.7) 38 (84.4) 124 (83.2)
Type 1 2 (1.9) 1 (2.2) 2 (2.0)
Unclassiﬁed 16 (15.4) 6 (13.3) 22 (14.8)
Duration of DM, years
Mean (SD) 8.1 (8.9) 6.8 (8.2) 7.7 (8.7)
Median (IQR) 5.0 4.0 5.0
FBGb
Mean (SD) 205.9 (100.7) 184.9 (55.6) 198.5 (87.4)
Median (IQR) 197.5 (124.5) 170.2 (76.5) 178.0 (105.0)
Tertiles of mean FBG
<153 10 (9.6) 5 (11.1) 15 (10.1)
153–252 16 (15.4) 10 (22.2) 26 (17.5)
>252 7 (6.7) 3 (6.7) 10 (6.7)
No measures 71 (68.3) 27 (60.0) 98 (65.8)
Prior DM medicationc
Insulin or oral agent 55 (52.9) 24 (53.3) 79 (53.0)
None/unknown 49 (47.1) 21 (46.7) 70 (47.0)
Any DM complicationsd
Yes 28 (26.9) 10 (22.2) 38 (25.5)
No 76 (73.1) 35 (77.8) 111 (74.5)
Ever DM hospitalization
Yes 7 (6.7) 5 (11.1) 12 (8.1)
No 97 (93.3) 40 (88.9) 137 (91.9)
Risk factorse
HIV-positive 0 0 0
Any household TB contactf 4 (3.9) 6 (13.3) 10 (6.7)
Household MDR contactf 1 (1.0) 6 (13.3) 7 (4.7)
Current tobacco 5 (4.8) 2 (4.4) 7 (4.7)
Current alcohol 4 (3.9) 2 (4.4) 6 (4.0)
Low BMI (<18.5 kg/m2) 6 (5.8) 3 (6.8) 9 (6.1)
Previous TB treatmentf 18 (17.3) 14 (31.1) 32 (21.5)
>1 MDR risk factorg 11 (10.6) 9 (20.0) 20 (13.4)
BMI, body mass index; DM, diabetes mellitus; DR, drug-resistant; FBG, fasting blood
glucose; IQR, interquartile range; MDR, multidrug-resistant; SD, standard devia-
tion; TB, tuberculosis.
a Includes 16 DR and 29 MDR patients.
b Fasting blood glucose (FBG): mean of FBG measures taken before TB treatment;
18/45 resistant patients and 33/104 susceptible had measurements available.
c Prior DM medication: insulin, oral hypoglycemic agents, or both taken prior to
study enrollment.
d Complications: include poor glycemic control, eye disease, renal failure,
cardiovascular disease, peripheral neuropathy, or hospitalization due to DM before
study enrollment.
e Not mutually exclusive categories, should not add up to 100%, column
percentages are listed.
f Mantel–Haenszel p-value <0.05.
g Greater than one MDR-TB risk factor identiﬁed by the Peruvian National TB
Control Program.
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susceptibility testing results were available for 1190 patients; 394
(33.1%) of these had MDR-TB. One-hundred and eighty-six patients
(11.1%) had diabetes.
TB–DM patients were signiﬁcantly more likely than those
without diabetes to be older (median age in years 54 (range 31–80)
vs. 39 (range 15–83)), married or partnered (65.6% vs. 35.1%), and
have less than a primary education (25.8% vs. 11.5%) (Table 1). They
were also less likely to have had previous TB treatment (23.1% vs.
54.2%). TB–DM patients had a signiﬁcantly lower proportion of
bilateral lung cavitations (3.2% vs. 5.1%) compared to TB patients
without diabetes (p < 0.05). More TB–DM patients than TB
patients without diabetes had positive cultures at baseline
(p < 0.05). TB–DM patients were also signiﬁcantly less likely to
have HIV infection (0.5% and 13.3%) and to be undernourished
(BMI < 18.5 kg/m2) (4.8% vs. 22.2%). Overall, TB–DM patients were
signiﬁcantly less likely than those without diabetes to have MDR-
TB (15.6% vs. 24.6%, p < 0.01). Because of the strong inﬂuence of
previous TB treatment on drug resistance status, we examined the
relationship between diabetes and drug resistance stratiﬁed by
treatment history (Figure 2), and among those with previous TB
treatment, 27.9% of TB–DM patients and 26.1% without diabetes
had MDR-TB at baseline.
3.2. Characteristics of TB–DM patients by drug resistance pattern
Of the 186 adult TB–DM patients in the study, 149 (80.1%) had
complete baseline TB drug susceptibility data. Of these, 104 (69.8%)
had drug-susceptible TB and 45 (30.2%) had drug-resistant TB, of
whom 29 had MDR-TB (Table 2). There were no signiﬁcant
differences in the demographic or TB characteristics (data not
shown) or diabetes characteristics (Table 2) comparing TB–DMpatients with and without drug-resistant TB. However, a signiﬁ-
cantly greater proportion of patients with any drug-resistant TB
had a household contact with TB (13.3% vs. 3.9%), including MDR-
TB (13.3% vs. 1.0%), and were more likely to have been previously
treated for TB (31.1% vs. 17.3%) (p < 0.05 for all comparisons).
3.3. Clinical and diabetes care characteristics by TB treatment
outcomes among TB–DM patients
Complete TB treatment outcome data were available for 136
(73.1%) TB–DM patients (Figure 1). Of these, 107 (78.7%) had a
favorable outcome (cured, completed treatment, or converted
cultures) and 29 (21.3%) had a poor outcome (failed, default, or
death) (Table 3). Diabetes care during TB treatment differed across
treatment outcome groups: among patients with favorable TB
treatment outcomes, 67.3% received diabetes management with
Table 3
Clinical and diabetes care by tuberculosis treatment outcome among tuberculosis patients with diabetes in Lima, Peru, 2005–2008 (N = 136)
Characteristic Favorable:
Cure, complete,a n (%)
(n = 107; 78.7%)
Poor:
Failed, default, died, n (%)
(n = 29; 21.3%)
Total, n (%)
(N = 136; 100%)
Before TB treatment
Type of DM
Type 2 90 (84.1) 25 (86.2) 115 (84.6)
Type 1 3 (2.8) 0 3 (2.2)
Unclassiﬁed 14 (13.1) 4 (13.8) 18 (13.2)
DM duration, years
Mean (SD) 8.2 (8.7) 8.9 (10.1) 8.1 (8.7)
Median (IQR) 5.5 (8.0) 5.0 (8.0) 5.5 (7.0)
Mean FBG
Mean (SD) 188.9 (75.8) 243.1 (127.5) 198.5 (87.4)
Median (IQR) 178.0 (94.7) 230.0 (149.7) 178.0 (105.0)
Tertiles of mean FBGb
<153 11 (10.3) 3 (10.3) 15 (10.7)
153–252 21 (19.6) 2 (6.9) 26 (17.5)
>252 5 (4.7) 5 (17.2) 10 (6.7)
No measures 70 (65.4) 19 (65.5) 98 (65.8)
Prior DM medication
Insulin or oral agent 59 (55.1) 15 (51.7) 74 (54.4)
None/unknown 48 (44.9) 14 (48.3) 62 (45.6)
Any DM complications
Yes 17 (15.9) 3 (10.3) 20 (14.7)
No 90 (84.1) 26 (89.7) 116 (85.3)
Ever DM hospitalization
Yes 11 (10.3) 0 11 (8.1)
No 96 (89.7) 29 (100.0) 125 (91.9)
During TB treatment
Mean FBG
Mean (SD) 175.9 (52.0) 157.4 (76.2) 170.3 (58.4)
Median (IQR) 169.7 (73.0) 161.0 (120.6) 162.3 (89.0)
Tertiles of mean FBGb
<136 11 (10.3) 5 (17.2) 20 (13.4)
136–214 25 (23.4) 3 (10.3) 28 (18.8)
>214 10 (9.4) 3 (10.3) 15 (10.1)
No measures 61 (57.0) 18 (62.1) 86 (57.7)
Glucose control
Below median 20 (18.7) 5 (17.2) 25 (18.4)
Above median 26 (24.3) 6 (20.7) 32 (23.5)
No documentation 61 (57.0) 18 (62.1) 79 (58.1)
Record mentioned control
Controlled 31 (29.0) 9 (31.0) 40 (29.4)
Not controlled/no mention 76 (71.0) 20 (69.0) 96 (70.6)
Managementc
Diet or medicine 72 (67.3) 13 (44.8) 85 (62.5)
None/missing 35 (32.7) 16 (55.2) 51 (37.5)
DM medications
Any 81 (75.7) 17 (58.6) 98 (72.1)
None 26 (24.3) 12 (41.4) 38 (27.9)
DM medicationsc
Insulin 10 (9.4) 6 (20.7) 16 (11.8)
Oral hypoglycemic 48 (44.9) 8 (27.6) 56 (41.2)
Both 23 (21.5) 3 (10.3) 26 (19.1)
None 26 (24.3) 12 (41.4) 38 (27.9)
Endocrinologist visit
Yes 36 (33.6) 6 (20.7) 42 (30.9)
No/missing 71 (66.4) 23 (79.3) 94 (69.1)
Any complicationsd
Yes 22 (20.6) 3 (10.3) 25 (18.4)
No 85 (79.4) 26 (89.7) 111 (81.6)
DM care during TB treatmente
Frequent care 35 (32.7) 5 (17.2) 40 (29.4)
Some care 48 (44.9) 12 (41.4) 60 (44.1)
None 24 (22.4) 12 (41.4) 36 (26.5)
Other measures
Drug susceptibilityc
DR 18 (16.8) 19 (65.5) 37 (27.2)
Susceptible 89 (83.2) 10 (34.5) 99 (72.8)
BMI, kg/m2
<18.5 6 (5.6) 2 (6.9) 8 (5.9)
18.5–24.99 58 (54.2) 15 (51.7) 73 (53.7)
25–29.99 34 (31.8) 9 (31.0) 43 (31.6)
30 9 (8.4) 2 (6.9) 11 (8.1)
Age
Mean (SD) 54.7 (9.8) 50.8 (10.8) 53.9 (10.1)
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Table 3 (Continued )
Characteristic Favorable:
Cure, complete,a n (%)
(n = 107; 78.7%)
Poor:
Failed, default, died, n (%)
(n = 29; 21.3%)
Total, n (%)
(N = 136; 100%)
Median (IQR) 55.0 (13.0) 49.0 (14.0) 54.0 (14.0)
BMI, body mass index; DM, diabetes mellitus; DR, drug-resistant; FBG, fasting blood glucose; IQR, interquartile range; SD, standard deviation; TB, tuberculosis.
a Or if no outcome, culture conversion result.
b Mean of patient fasting blood glucose measures.
c Mantel–Haenszel general association p-value <0.05.
d Any complications from glycemic control, eye disease, renal insufﬁciency, cardiovascular disease, peripheral neuropathy, or hospitalization due to DM.
e DM care during TB treatment: combines during-treatment measures of endocrinologist visit, mentioned DM control, recorded DM medications, or 3 measures of blood
glucose. ‘Frequent care’ indicates three or four of the during-treatment measures, ‘Some care’ indicates one or two, and ‘None’ indicates 0.
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treatment outcome (p < 0.05). More TB–DM patients with a
favorable TB treatment outcome received an oral hypoglycemic
(44.9%) or both an oral hypoglycemic and insulin (21.5%), but fewer
received insulin alone (9.4%) compared to those with poor TB
treatment outcomes (27.6%, 10.3%, and 20.7%, respectively);
however, overall more TB–DM patients with a favorable treatment
outcome received any diabetes medications during TB treatment
(75.5%) compared to those with a poor TB treatment outcome
(58.6%) (p = 0.07). While 89.9% of TB–DM with drug-susceptibleFigure 3. (A) Kaplan–Meier curves for time until tuberculosis (TB) culture conversion fro
mellitus (n = 149); control status determined by medical record indication. (B) Kaplan–M
control status among TB patients with diabetes mellitus who have been previously treate
positive to negative by diabetes control status among patients with diabetes mellitus disease had favorable outcomes, only 48.6% of those with drug-
resistant TB had favorable outcomes (p < 0.05).
Data for the time until TB culture conversion were available for
149 (80.0%) of the 186 TB–DM patients. The mean time to culture
conversion was 152 days and the median was 171 days (range 1–
300 days). Among TB–DM patients, those with documented
diabetes control during TB treatment converted TB cultures from
positive to negative more quickly (p < 0.01) than patients without
any record of diabetes control (Figure 3, A–C). After stratiﬁcation
by TB treatment history, among TB–DM patients with no history ofm positive to negative by diabetes control status among TB patients with diabetes
eier curves for time until TB culture conversion from positive to negative by diabetes
d for TB (n = 32). (C) Kaplan–Meier curves for time until TB culture conversion from
who have not been previously treated for TB (n = 117).
Table 4
Hazard ratio of time to culture conversion among tuberculosis patients with diabetes mellitus, Peru 2005–2008 (N = 149)
Hazard ratio (95% CI) Adjusted hazard ratioa (95% CI)
Record mentioned control
Controlled 2.5 (1.3, 4.6) 2.2 (1.1, 4.1)
Not controlled/no mention 1 1
DM care during TB treatmentb
Frequent care 2.1 (1.2, 4.2) 1.8 (0.9, 3.7)
Some care 1 1
None 0.7 (0.2, 2.0) 0.8 (0.3, 2.3)
CI, conﬁdence interval; DM, diabetes mellitus; TB, tuberculosis.
a Adjusted for previous TB treatment and any drug resistance.
b DM care during TB treatment: combines during-treatment measures of endocrinologist visit, mentioned DM control, recorded DM medications, or 3 measures of blood
glucose. ‘Frequent care’ indicates three or four of the during-treatment measures, ‘Some care’ indicates one or two, and ‘None’ indicates 0.
M.J. Magee et al. / International Journal of Infectious Diseases 17 (2013) e404–e412e410previous TB treatment, those with documented diabetes control
converted sputum cultures more quickly (p = 0.01) (Figure 3, B and
C). After controlling for TB treatment history and drug susceptibil-
ity, the hazard rate of culture conversion among those
with documented diabetes control was 2.2 (95% conﬁdenceFigure 4. (A) Kaplan–Meier curves for time until tuberculosis (TB) culture conversion fro
diabetes mellitus (n = 149). Frequent diabetes care during TB treatment was deﬁned as at
record mentioned diabetes is controlled, recorded oral hypoglycemic agent or insulin u
deﬁned as one or two of the aforementioned measures and none was deﬁned as 0 of th
positive to negative by diabetes care during TB treatment among TB patients with diabete
for time until TB culture conversion from positive to negative by diabetes care during T
treated for TB (n = 117).interval 1.1, 4.1) times the rate of patients with no documented
control (Table 4). Similarly, Figure 4A shows that TB–DM patients
who received frequent diabetes care during TB treatment
converted cultures to negative more quickly than TB–DM patients
with no diabetes care (p < 0.05), and this signiﬁcant differencem positive to negative by diabetes care during TB treatment among TB patients with
 least three of the four following measures: at least one endocrinologist visit, medical
se, or 3 documented blood glucose exams. Some care during TB treatment was
ese measures. (B) Kaplan–Meier curves for time until TB culture conversion from
s mellitus who have been previously treated for TB (n = 32). (C) Kaplan–Meier curves
B treatment among patients with diabetes mellitus who have not been previously
M.J. Magee et al. / International Journal of Infectious Diseases 17 (2013) e404–e412 e411remained even after stratifying by treatment history (Figure 4, B
and C). After controlling for TB treatment history and drug
susceptibility, the hazard rate of culture conversion among those
with frequent diabetes care during TB treatment was 1.8 (95%
conﬁdence interval 0.9, 3.7) times the rate of patients with some
care during TB treatment (Table 4).
4. Discussion
In this study of a Peruvian cohort of TB patients at increased risk
of MDR-TB, we evaluated the role of diabetes in TB clinical
presentation, drug resistance patterns, and treatment outcomes.
Among TB patients enrolled in this cohort, 11.1% had diabetes.
Furthermore, 11.9% of never previously treated and 27.9% of
previously treated TB–DM patients had MDR-TB. Among TB–DM
patients we found that drug-resistant TB was associated with
having a household TB contact and previous TB treatment, and a
favorable TB treatment outcome was associated with diabetes
management, drug-susceptible TB, and receiving diabetes medica-
tions during TB treatment.
Consistent with previous studies, we found TB–DM patients
were more likely to be married or partnered, older, and less
educated than TB patients without diabetes.27–31 It is important for
health providers to better understand who may be at increased
likelihood of having a comorbid illness to better identify high-risk
patients and ensure they receive the necessary care for both
diseases. Patient-centered strategies to treatment, such as those
promoted in the International Standards for TB Care, should be
applied in the management of TB–DM patients.32
TB–DM patients were more likely to be culture-positive at the
time of diagnosis but less likely to have had previous TB treatment,
have MDR-TB, or have bilateral lung cavitation than TB patients
without diabetes. Although diabetes is known to modify clinical
features and radiological manifestations of pulmonary TB patients,
previous studies have reported inconsistent results.4,28,33 Previous
studies have reported a lower proportion of previous TB
treatment,34MDR-TB,33 and cavitation34,35 among TB–DM patients
compared to TB patients without diabetes, while other studies
have found the opposite.36,37 Because our cohort consisted of TB
patients with at least one risk factor for MDR-TB, our ﬁnding that
11.9% of never previously treated TB–DM patients had MDR-TB and
22.8% of never previously treated non-diabetes patients had MDR-
TB may not suggest a lack of association between MDR-TB and
diabetes, but rather may reﬂect a high prevalence of even stronger
risk factors than diabetes in our cohort.
Overall, almost 79% of TB–DM cases had a favorable outcome, a
result consistent with recent studies of TB–DM patient treatment
outcomes.34,38 We found favorable TB outcomes were associated
with receiving diabetes care, speciﬁcally the use of a provider-
indicated diet or medicine to manage diabetes, including the use of
an oral hypoglycemic or both an oral hypoglycemic and insulin.
Additionally, we showed that diabetes control and frequent
diabetes care during TB treatment resulted in a signiﬁcantly
shorter time to TB culture conversion. These results suggest that
regardless of the complex clinical care required for both diseases,
TB treatment effectiveness can be improved among TB patients
with well-managed diabetes.
Our ﬁndings suggest optimal diabetes control should be part of
TB–DM patient management in Peru. Furthermore, TB–DM
patients in Peru are at risk of MDR-TB, and screening for drug
resistance among TB–DM is the important ﬁrst step to effectively
diagnose MDR-TB in this group. With increasing access to rapid
diagnostics, universal screening for drug resistance is feasible for
the national TB program.
Given the high prevalence of diabetes in this cohort of TB
patients, our ﬁndings also support the importance of converselyscreening TB patients for diabetes. The detection of diabetes in TB
patients and linking these persons to care (management with diet
and/or medicine) may improve TB treatment outcomes. Addition-
ally, active TB screening among persons with diabetes, particularly
those with uncontrolled diabetes, may be worthwhile for TB
control in Peru, especially since diabetes patients visit their health
care providers more frequently compared to other groups at risk of
TB. Further studies are needed to assess the feasibility and cost-
effectiveness of such interventions.
There were several limitations in this study. First, patients were
selected for this study because of speciﬁc risk factors for drug-
resistant TB. Therefore, the observations reported in Table 1 cannot
be applied to the general TB population in Peru. Without a
comparison group representing the experience of general TB
patients without diabetes, our results only highlight differences in
patients with diabetes compared to other TB patients already
determined to have an increased MDR-TB risk. Previous TB
treatment was the strongest, most common risk factor for drug
resistance. The prevalence of TB drug resistance among patients
with diabetes was greater than its prevalence among TB patients in
general, but the magnitude of the increased risk was less than the
magnitude of increased risk associated with previous TB treat-
ment. Second, misclassiﬁcation of study patients by diabetes status
and diabetes clinical features is possible due to measurement
error. However, we do not have reason to believe any misclassiﬁ-
cation would be disproportionately distributed by factors related
to drug susceptibility or treatment outcome, consequently if bias
exists it is likely toward the null effect. Third, although this study
represents one of the largest reported TB–DM cohorts, missing
drug susceptibility and treatment outcome data precluded
multivariable analyses due to sample size.
Currently few published studies have examined diabetes
clinical and care characteristics associated with drug-resistant
TB, TB treatment outcome, or time to culture conversion. A
strength of this study is that it examined a large cohort of TB–DM
patients with detailed information on diabetes clinical history both
before and during TB treatment, including glucose levels, duration
of diabetes disease, type of diabetes management (including type
of medication used and access to endocrinologists), and reported
diabetes complications or hospitalizations. Our ﬁndings highlight
the importance of linking TB and diabetes diagnostic and
treatment services in Peru.
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